'Asha' means hope. FDA Oncology's Project Asha aims to increase oncology clinical trial access in India. India accounts for ~20% of the global population yet only 1.5% of global trials are conducted there. Lead: Geetika Srivastava MD MSPH
fda.gov/about-fda/onco…

#OCEProjectAsha

🌟 Explore the world of oncology & get free CME with Project Livin' Label! 🎓 Watch interesting discussions aimed at empowering the cancer community with deeper comprehension of oncology product labels for recent FDA approvals 🚀
fda.gov/about-fda/onco…

#MedEd #CME #FDAApproval

How is the Oncologic Drugs Advisory Committee an integral part of the FDA assessment? Click to watch the replay of a #ConversationsonCancer panel discussion, 'ODAC Chronicles - Past, Present, & Future of Oncology Advisory Committees.' #OCEProjectCommunity

youtube.com/live/MNZhNkt-x…

ICYMI: Watch the FDA Oncologic Drugs Advisory Committee discussion of minimal residual disease as an endpoint in multiple myeloma clinical trials.
Meeting info: fda.gov/advisory-commi…
Watch: youtube.com/watch?v=pooME9…

#FDAODAC

OCE's Project Confirm promotes the transparency of Accelerated Approval for oncology indications. Learn more: fda.gov/about-fda/onco…

🎗️ Join the Conversation on April 23! 🎗️

Mark your calendar for an insightful panel discussion on 4/23! We're bringing together experts and community leaders to delve into crucial topics surrounding cancer care access & education.
surveymonkey.com/r/GMRWVWM

#ConversationsonCancer

Did you know? Cancer is the second leading cause of death in America, claiming nearly 600,000 lives annually. Take charge of your health with small changes that can reduce your risk. From daily exercise to a balanced diet, every choice matters.
cancer.gov/about-cancer/c…

✍🏽 DYK? FDA Oncology medical reviewers wrote more than 500 articles for peer-reviewed journals from 2018-2023—articles about regulatory issues, drug approval summaries, and scientific analyses of clinical trial data. 💻
fda.gov/about-fda/onco…

#OCEPublications #OCECareers

Project Facilitate works with any regulatory or healthcare professional through the Expanded Access process. The call center is open M-F, 8:00 am to 4:30 pm, ET. fda.gov/about-fda/onco…

#ProjectFacilitate

Today the FDA Oncologic Drugs Advisory Committee voted 12-0 in favor of using minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials.
Meeting info: fda.gov/advisory-commi…
Watch: youtube.com/watch?v=pooME9…

#FDAODAC

Disparities in healthcare access based on factors like race, ethnicity, and socioeconomic status contribute to unequal cancer outcomes. Join us for a #ConversationsonCancer titled: Strength in Numbers - Increasing Awareness, Decreasing Disparities.
surveymonkey.com/r/GMRWVWM

How is the Oncologic Drugs Advisory Committee an integral part of the FDA assessment? Click to watch the replay of a #ConversationsonCancer panel discussion, 'ODAC Chronicles - Past, Present, & Future of Oncology Advisory Committees.' #OCEProjectCommunity

youtube.com/live/MNZhNkt-x…

Today, 4/12, 9a-4p ET: FDA Oncologic Drugs Advisory Committee discusses minimal residual disease as an endpoint in multiple myeloma clinical trials.
Meeting info: fda.gov/advisory-commi…
Watch: youtube.com/watch?v=pooME9…

#FDAODAC

In 2023, OCE's #ProjectFacilitate handled 401 phone calls and 889 Expanded Access applications. Learn more in the #OCEAnnualReport .

fda.gov/about-fda/2023…

#CancerMoonshot #OCEAnnualReport

Meeting materials are available for tomorrow's Oncologic Drugs Advisory Committee meeting on minimal residual disease as an endpoint in multiple myeloma clinical trials to support accelerated approval of a new product or a new indication. fda.gov/advisory-commi…

#FDAODAC

🎗️ Join the Conversation on April 23! 🎗️

Mark your calendar for an insightful panel discussion on 4/23! We're bringing together experts and community leaders to delve into crucial topics surrounding cancer care access & education.
surveymonkey.com/r/GMRWVWM

#ConversationsonCancer

In case you missed FDA Oncology presentations at the #AACR24 Annual Meeting, you can find links to them here.
fda.gov/about-fda/onco…

#OCETalks

Understanding the importance of early detection and equitable access to care is crucial in our fight against cancer. Join us for #ConversationsonCancer : Strength in Numbers - Increasing Awareness, Decreasing Disparities on April 23. surveymonkey.com/r/GMRWVWM

#OCEProjectCommunity

Any oncology healthcare professional needing assistance with FDA Expanded Access may contact our Project Facilitate call center. You do not have to be an academic investigator. This project aims to assist hcps throughout the process. #ProjectFacilitate
fda.gov/about-fda/onco…

#AACR24 Join FDA, EMA, industry, academia & advocacy to discuss considerations for approval in a biomarker-defined population vs approving for the overall population. Putting the Precision Back in Precision Oncology 12:30 pm PT, Tues 4/9 SDCC Rm1
abstractsonline.com/pp8/#!/20272/s…
#OCETalks